fashion -WSS

fashion

author：Wikipedia 2025-09-06 03:54:13 - browse：8

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Dozens dead from Maui wildfires: What we know about the victims

WSS

Health AI: on the border between health care and tech

Supreme Court mifepristone arguments center on docs' right to sue

Biden administration begins canceling student loan debt for 804,000 borrowers

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Patients, digital health players weigh in on FTC's data privacy plan

hotspot

fashion

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Schizophrenia gene found to be linked to cells' energy dysfunction

Jerome Adams on the need for new antivirals for Covid

FDA's naming rule on biosimilars has undermined competition

Wildfire smoke exposes gaps in outdoor worker protections

Dozens dead from Maui wildfires: What we know about the victims

Affirmative action in medical school literally saved lives

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Anesthesiologist group: stop taking Ozempic before surgery

The Readout: Lenmeldy, GLP

leisure time

Patients, digital health players weigh in on FTC's data privacy plan

Aspartame and sugar

Biogen’s boardroom scandal saddles CEO with first crisis

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Steward Health Care has deal to sell doctor network to UnitedHealth

hotspot

explore

focus

focus